参考文献/References:
[1]Wu XX,Yao HP,Wu NP,et al.Ebolavirus Vaccines: Progress in the Fight Against Ebola Virus Disease[J].Cell PhysiolBiochem,2015,37(5):1641-1658. [2]Malvy D,McElroy AK,de Clerck H,et al.Ebola virus disease[J].Lancet,2019,393(10174):936-948. [3]Geisbert TW,Pushko P,Anderson K,et al.Evaluation in nonhuman primates of vaccines against Ebola virus[J].Emerg Infect Dis,2002,8(5):503-507. [4]Gross L,Lhomme E,Pasin C,et al.Ebola vaccine development:Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination[J].Int J Infect Dis,2018(74):83-96. [5]Garbutt M,Liebscher R,Wahl-JensenV,et al.Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses[J].J Virol,2004,78(10):5458-5465. [6]Marzi A,Robertson SJ,Haddock E,et al.VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain[J].Science,2015,349(6249):739-742. [7]Marzi A,Mire CE.Current Ebola Virus Vaccine Progress[J]. BioDrugs,2019,33(1):9-14. [8]Kennedy SB,Bolay F,Kieh M,et al.Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia[J].N Engl J Med,2017,377(15):1438-1447. [9]HenaoRestrepo AM,Longini IM,Egger M,et al.Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-randomisedtrial[J].Lancet,2015,386(9996):857-866. [10]HenaoRestrepo AM,Camacho A,Longini IM,et al.Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease:final results from the Guinea ring vaccination, open-label,cluster-randomised trial[J].Lancet,2017,389(10068):505-518. [11]Gsell PS,Camacho A,Kucharski AJ,et al.Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea,2016:an operational and vaccine safety report[J].Lancet Infect Dis,2017,17(12):1276-1284. [12]Halperin SA,Arribas JR,Rupp R, et al.Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults[J].J Infect Dis,2017,215(12):1789-1798. [13]Ewer K,Rampling T,Venkatraman N,et al.A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boostedwith MVA[J].N Engl J Med,2016,374(17):1635-1646. [14]Tapia MD,Sow SO,Lyke KE,et al.Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo:a phase 1,single-blind,randomised trial,a phase 1b, open-label and double-blind,dose-escalation trial,and a nested,randomised,double-blind, placebo-controlled trial[J].Lancet Infect Dis,2016,16(1):31-42. [15]Milligan ID,Gibani MM,Sewell R,et al.Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines:A Randomized Clinical Trial[J].JAMA,2016,315(15):1610-1623. [16]Winslow RL,Milligan ID,Voysey M,et al.Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year[J].JAMA,2017,317(10): 1075-1077. [17]Mutua G,Anzala O,Luhn K,et al.Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BNFilo Ebola Vaccines:12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya[J].J Infect Dis,2019,220(1):57-67. [18]Zhu FC,Hou LH,Li JX,et al.Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary reportofarandomised,double-blind,placebo-controlled,phase 1 trial[J].Lancet,2015,385(9984):2272-2279. [19]Li JX,Hou LH,Meng FY,et al.Immunity duration of a recombinant adenovirus type-5vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial[J].Lancet Glob Health,2017,5(3):e324-e334. [20]Dolzhikova IV,Zubkova OV,Tukhvatulin AI,et al.Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phaseⅠ/Ⅱ trial in healthy adults in Russia[J].Hum VaccinImmunother,2017,13(3):613-620. [21]FeldmannH,Feldmann F,Marzi A.Ebola:Lessons on Vaccine Development[J].Annu Rev Microbiol, 2018(72):423-446. [22]Vanderzanden L,Bray M,Fuller D,et al.DNAvaccines expressing either the GP or NP genes of Ebolavirus protect micefrom lethal challenge[J].Virology,1998,246(1):134-144. [23]Grant Klein RJ,Altamura LA,Badger CV,et al.Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges[J].Hum VaccinImmunother,2015,11(8):1991-2004. [24]Warfield KL,Bosio CM,Welcher BC,et al.Ebola virus-like particles protect from lethal Ebola virus infection[J].ProcNatlAcadSci U S A,2003,100(26):15889-15894. [25]Warfield KL,Swenson DL,Olinger GG,et al.Ebola Virus-Like Particle-Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus Challenge[J].J Infect Dis,2007(196 Suppl 2):S430-S437. [26]Warfield KL,Dye JM,Wells JB,et al.Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles[J].PLoS One,10(3):e0118881. [27]Konduru K,Bradfute SB,Jacques J,et al.Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice[J].Vaccine,2011,29(16):2968-2977. [28]Liu Y,Ye L,Lin F,et al.Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge[J].Sci Rep,2018,8(1):11193. [29]Liu Y,Ye L,Lin F,et al.Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge[J].J Infect Dis,2018,218(suppl_5):S545-S552. [30]Halfmann P,Ebihara H,Marzi A,et al.Replication-Deficient Ebolavirus as a Vaccine Candidate[J].J Virol,2009,83(8):3810-3815. [31]Marzi A,Halfmann P,Hill-Batorski L,et al. An Ebola whole-virus vaccine is protective in nonhuman primates[J].Science,2015,348(6233):439-442.
相似文献/References:
[1]刘琳琳,宫 正,杨海嵘,等.宫颈癌的诊治及预防研究[J].医学信息,2021,34(03):49.[doi:10.3969/j.issn.1006-1959.2021.03.015]
LIU Lin-lin,GONG Zheng,YANG Hai-rong,et al.Research on Diagnosis,Treatment and Prevention of Cervical Cancer[J].Medical Information,2021,34(01):49.[doi:10.3969/j.issn.1006-1959.2021.03.015]
[2]万久琴,戴 澄.2020年江都区疑似预防接种异常反应发生情况分析[J].医学信息,2021,34(21):144.[doi:10.3969/j.issn.1006-1959.2021.21.040]
WAN Jiu-qin,DAI Cheng.Analysis on Incidence of Suspected Immunization Abnormal Reaction in Jiangdu District in 2020[J].Medical Information,2021,34(01):144.[doi:10.3969/j.issn.1006-1959.2021.21.040]
[3]孔祥忍,毛双双,刘欣宇,等.新型佐剂-细菌样颗粒对百日咳抗原体液免疫的效果研究[J].医学信息,2021,34(02):95.[doi:10.3969/j.issn.1006-1959.2021.02.025]
KONG Xiang-ren,MAO Shuang-shuang,LIU Xin-yu,et al.Study on the Effect of New Adjuvant-bacteria-like Particles on Pertussis Antigen Humoral Immunity[J].Medical Information,2021,34(01):95.[doi:10.3969/j.issn.1006-1959.2021.02.025]
[4]郝宝云.水痘-带状疱疹疫苗的应用现状研究[J].医学信息,2021,34(15):22.[doi:10.3969/j.issn.1006-1959.2021.15.006]
HAO Bao-yun.Study on the Application Status of Varicella-zoster Vaccine[J].Medical Information,2021,34(01):22.[doi:10.3969/j.issn.1006-1959.2021.15.006]
[5]翁梦晴,韦彩萍,任文宁,等.基于CiteSpace的人乳头瘤病毒疫苗可视化分析[J].医学信息,2023,36(03):39.[doi:10.3969/j.issn.1006-1959.2023.03.009]
WENG Meng-qing,WEI Cai-ping,REN Wen-ning,et al.Visual Analysis of Human Papillomavirus Vaccine Based on CiteSpace[J].Medical Information,2023,36(01):39.[doi:10.3969/j.issn.1006-1959.2023.03.009]
[6]徐闪闪,梁 杰,郑晓艳,等.2015-2019年扬州市疑似预防接种异常反应监测分析[J].医学信息,2022,35(02):154.[doi:10.3969/j.issn.1006-1959.2022.02.039]
XU Shan-shan,LIANG Jie,ZHENG Xiao-yan,et al.Analysis on the Surveillance of Adverse Events Following Immunizationin Yangzhou City from 2015 to 2019[J].Medical Information,2022,35(01):154.[doi:10.3969/j.issn.1006-1959.2022.02.039]